Biomarker Discovery and Ongoing Research

To ensure robust and reliable diagnostic (Dx) and therapeutic (Rx) pipelines it is vital to support ongoing research in biomarker discovery, and diagnostic and companion diagnostic test development. It is in this capacity where Invivoscribe is on the forefront leading the way. 

Invivoscribe consistently commits substantial resources to continue to understand the changes that occur in biomarkers at the molecular level in response to drug treatment and therapy. We feel it is a moral imperative and the socially responsible way forward.

Invivoscribe and its subsidiaries have invested and committed substantial resources to ensure we adequately and completely investigate and understand the changes that occur in biomarkers at the molecular level in response to drug treatment and therapy. No other company in the Personalized Molecular Diagnostics area has made such a commitment. 

Currently, we are working to develop and validate a companion diagnostic for the FLT3 biomarker and we have commited resources to identify additional mutations in FLT3 and other of our IP protected, clinically-relevant biomarkers.